
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, cardiovascular disease, inflammation, bone health and rare disease markets.
On the other hand, Novo Nordisk enjoys a leading position in the diabetes and obesity market, while steadily expanding its presence into rare diseases.
Both these giants have established strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for AMGN
Amgen's diverse portfolio and global reach position it well in a changing pharma landscape. Growth products like Repatha, Prolia, Xgeva, Evenity, Vectibix, Nplate, Kyprolis and Blincyto are performing well, having gained approvals for label expansions. The robust sales of these drugs have helped Amgen offset the declining sales of its legacy drugs such as Enbrel.
The 2023 acquisition of Horizon Therapeutics has significantly expanded Amgen's rare disease business by adding several rare disease drugs, including Tepezza, Krystexxa and Uplizna, to its portfolio.
Amgen is one of the handful of companies that is evaluating an obesity drug in late-stage development. In March, the company started two phase III studies evaluating its investigational GIPR/GLP-1 receptor MariTide for 72 weeks in people with obesity, with or without type II diabetes (T2D). Additional late-stage studies on the drug in specific obesity-related conditions are expected to start throughout 2025.
Unlike the currently marketed obesity drugs like Novo's Wegovy and Eli Lilly 's LLY Zepbound that require weekly injections, MariTide is being tested for monthly dosing. The late-stage development of the drug was supported by data from phase II studies, wherein treatment with MariTide resulted in up to approximately 20% average weight loss over 52 weeks, without reaching a weight loss plateau in people who were obese or overweight but without T2D. However, the weight loss reduction was at the lower end of investor expectations of 20-25%. In T2D patients who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks.
Beyond obesity, Amgen has promising late-stage pipeline drugs across several therapeutic areas, which represent significant commercial potential. These include bemarituzumab (for first-line gastric cancer), rocatinlimab (for eczema and prurigo nodularis) and olpasiran (for atherosclerotic cardiovascular disease).
Amgen has also strengthened its biosimilar portfolio, with the recent launches of biosimilar versions of popular drugs like J&J's Stelara (marketed as 'Wezlana') and Regeneron's Eylea ('Pavblu'). It is also developing biosimilar versions of blockbuster oncology drugs like Bristol Myers' Opdivo and Merck's Keytruda in ongoing phase III studies.
However, increased pricing headwinds and competitive pressure are negatively impacting the sales of many products. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025, mainly from the second half, due to patent erosion.
The Case for NVO
Novo Nordisk has achieved tremendous success in the GLP-1 space, all thanks to its semaglutide drugs sold under the brand names Ozempic (for T2D) and Wegovy (for obesity). As of March 2025-end, Novo continues to be the global market leader in the GLP-1 segment, with around 54% value market share.
Sales of Wegovy continue to rise due to strong prescription growth, driving higher revenues and profits. Additionally, Ozempic sales are also contributing positively to overall revenues. NVO has been investing heavily to expand its manufacturing capacity as part of its strategic move to entrench its diabetes and obesity care market leadership for its GLP-1 products.
Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease. It is also investigating semaglutide's potential in metabolic dysfunction–associated steatohepatitis (MASH). These efforts could expand the eligible patient population for semaglutide and boost sales.
However, the company's arch-rival Eli Lilly remains a formidable adversary in the obesity market, which threatens its market share. Lilly markets its tirzepatide injections under the brand names Mounjaro for T2D and Zepbound for obesity.
The NVO stock has also been under pressure due to disappointing data from two late-stage studies for its next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. In these studies, CagriSema demonstrated a lower-than-expected reduction in body weight. Novo Nordisk is also currently facing a major transition in its executive management, as CEO Lars Fruergaard Jørgensen will step down due to market headwinds and a decline in the company's stock since mid-2024. The search for his successor is currently underway.
Though the rare disease segment currently accounts for a minimal portion of revenues, Novo is making good efforts to expand this portfolio. A regulatory filing with the FDA, seeking approval for Mim8 in patients aged 12 years and older with hemophilia A, is planned for submission later this year.
How Do Estimates Compare for AMGN & NVO?
The Zacks Consensus Estimate for Amgen's 2025 sales implies a year-over-year increase of 5%, and that for EPS also suggests an improvement of 5%. EPS estimates for 2025 and 2026 have moved north in the past 60 days.
The Zacks Consensus Estimate for Novo's 2025 sales and EPS implies a year-over-year increase of around 20% and 21%, respectively. While EPS estimates for 2025 have been trending upward over the past 60 days, the same for 2026 have moved south.
Price Performance and Valuation of AMGN & NVO
Year to date, shares of Amgen have gained 17%, while those of Novo have plummeted 22%. In comparison, the industry has declined 3%, as seen in the chart below.
From a valuation standpoint, Novo Nordisk seems to be slightly more expensive than Amgen, going by the price/book (P/E) ratio. NVO's shares currently trade at 15.51 times forward earnings, higher than 14.5 for AMGN.
In terms of dividend yield, Amgen stands higher at 3.1% compared to Novo's 2.5%.
AMGN or NVO: Which Is a Better Pick?
Both Amgen and Novo carry a Zacks Rank #3 (Hold) each, which makes choosing one stock over the other difficult. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
However, when comparing the two, Amgen appears to be the better pick. Despite short-term headwinds like Prolia and Xgeva going off patent later this year, the company's diversified portfolio and deep pipeline offer a balanced growth story. AMGN stock also looks more attractive than NVO from a valuation standpoint.
While Novo Nordisk continues to lead in the GLP-1 space with strong revenue growth, it faces several near-term challenges. These include limited diversification, underwhelming CagriSema results and a leadership transition — all of which may weigh on investor sentiment.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 hours ago
- Globe and Mail
ADT, Inc. Reports Strong Q2 Earnings Amid Challenges
Adt, Inc. ((ADT)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ADT, Inc. recently held its earnings call, revealing a positive sentiment driven by strong financial performance. The company reported record recurring revenue, increased cash flow, and successful strategic acquisitions. Despite facing challenges, particularly in the State Farm partnership and dealer channel performance, ADT's robust cash generation, customer satisfaction, and strategic execution helped offset these issues. Record Recurring Monthly Revenue ADT announced a record recurring monthly revenue balance of $363 million, marking a 2% increase year-over-year. This achievement underscores the company's steady growth and its ability to maintain a strong revenue stream. Total Revenue Growth The company reported a total revenue increase of 7% year-over-year, highlighting its successful strategies in expanding its market presence and enhancing its financial performance. Strong Cash Flow ADT's adjusted free cash flow, including interest rate swaps, reached $500 million through the first half of the year, up 38%. This significant increase in cash flow demonstrates the company's financial health and its capacity to invest in future growth opportunities. Increased Adjusted Earnings Per Share The company saw a 35% increase in adjusted earnings per diluted share, reaching $0.23. This improvement reflects ADT's effective cost management and revenue growth strategies. Customer Retention and Satisfaction Customer attrition remained solid at 12.8%, and ADT achieved a record Net Promoter Score (NPS) in June, indicating high levels of customer satisfaction and loyalty. Successful Strategic Acquisition ADT completed a strategic acquisition of approximately 50,000 subscribers for $89 million, further expanding its customer base and enhancing its market position. Strong Partnership with Google The partnership with Google continues to thrive, with the Nest Aware subscriber base surpassing 1 million customers, showcasing strong collaboration and increased adoption of smart home technologies. AI Adoption in Customer Service ADT has embraced AI in customer service, with 90% of customer service chats processed by AI agents. Nearly half of these interactions were resolved without live agent involvement, improving efficiency and customer experience. Underperformance of State Farm Partnership The State Farm partnership generated slightly more than 30,000 subscribers, falling short of projections. This underperformance highlights a challenge that ADT is working to address. Challenges in Dealer Channel The dealer channel experienced a year-over-year decline, though this was mitigated by bulk acquisitions, demonstrating ADT's adaptability in managing channel performance. Fluctuations in Nonpayment and Voluntary Cancellations There were modest increases in nonpayment cancellations and voluntary cancellations, indicating areas for potential improvement in customer retention strategies. Tariff Exposure Potential tariffs could impact ADT's financials, but the company remains confident in its ability to manage within full-year guidance ranges. Forward-Looking Guidance During the earnings call, ADT reaffirmed its full-year guidance, with expectations for total revenue, adjusted EBITDA, and adjusted free cash flow. The company also raised its adjusted earnings per share guidance by $0.04 to a range of $0.81-$0.89 per share, reflecting confidence in its ongoing growth strategies. In summary, ADT's earnings call conveyed a positive outlook, with strong financial performance and strategic initiatives driving growth. Despite some challenges, the company's robust cash flow, customer satisfaction, and strategic partnerships position it well for future success.


Globe and Mail
2 hours ago
- Globe and Mail
Chubb Ltd Reports Record Earnings and Strong Growth
Chubb Ltd ((CB)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Chubb Ltd's recent earnings call painted a picture of robust financial health, marked by record-breaking earnings per share (EPS), underwriting income, and international premium growth. Despite facing challenges such as competitive pressures in large account property markets and softening financial lines pricing, the overall sentiment was overwhelmingly positive, underscoring the company's strong performance. Record Operating EPS Chubb Ltd achieved a milestone with its core operating EPS reaching a record $6.14, reflecting a 14% increase from the previous year. This impressive growth underscores the company's effective strategies and operational efficiency. Strong Core Operating Income The company reported a record core operating income of $2.5 billion, marking a 13% increase year-over-year. This significant growth highlights Chubb's ability to generate substantial revenue from its core operations. Impressive Underwriting Income Underwriting income soared to $1.6 billion, up 15% from the prior year, resulting in a combined ratio of 85.6%. This improvement indicates a strong underwriting performance and effective risk management. Significant Tangible Book Value Growth Chubb Ltd's tangible book value per share grew by an impressive 23.7% from a year ago and 8% from the previous quarter, showcasing the company's strong financial foundation and shareholder value enhancement. Robust Premium Growth in Life Insurance The Life Insurance division saw premiums grow by nearly 17.5%, reflecting Chubb's successful expansion and market penetration in this sector. Continued Growth in International Markets Chubb's international markets demonstrated strong performance, with premiums in Asia growing over 12.5%, Europe over 8%, and Latin America over 17%. This growth highlights the company's effective global strategy and market diversification. Strong Cash Flow and Investment Income Operating cash flow was robust at $3.2 billion, and adjusted net investment income rose by 8% to nearly $1.7 billion. These figures underscore Chubb's strong cash generation capabilities and investment acumen. Competitive Large Account Property Market The large account-related short-tail business has become increasingly competitive, with softening prices posing challenges. However, Chubb remains focused on maintaining its market position. Property Pricing Pressure Property pricing experienced a decline of 2.5%, with rates down about 7%, offset by an exposure change of 4.9%. This trend reflects the competitive nature of the property market. Softness in Financial Lines Pricing Financial lines pricing faced softness, with a 1.2% decrease in North America and over 6.5% internationally. Chubb continues to navigate these challenges while seeking opportunities for growth. Catastrophe Losses Chubb reported pretax catastrophe losses of $630 million for the quarter, highlighting the impact of unforeseen events on the company's financials. Forward-Looking Guidance Looking ahead, Chubb Ltd remains optimistic about its growth prospects. The company anticipates continued strong financial performance, with a diversified global presence supporting its expansion. The global P&C premiums are expected to grow, with notable increases in consumer P&C and Life Insurance premiums. Despite a competitive U.S. commercial P&C market, Chubb is well-positioned for sustained growth. In conclusion, Chubb Ltd's earnings call reflects a strong positive sentiment, driven by record financial metrics and strategic growth in international markets. While challenges in pricing and competition exist, the company's robust performance and forward-looking strategies suggest a promising future.


Globe and Mail
2 hours ago
- Globe and Mail
Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control?
Shares of had been grinding higher into Wednesday night's earnings, up nearly 15% over the past two weeks and more than 50% since April. That kind of run can easily put investors on edge, as they know a lot is going to be riding on the company's next earnings report. With Tesla's previous two earnings reports delivering big misses, Wall Street was hoping for a change of tone this time around. On paper, the electric vehicle (EV) giant delivered. Revenue still declined nearly 12% year-over-year, but not as badly as expected, and non-GAAP EPS came in at $0.40, which was solidly in the black. Deliveries were up compared to Q1, and margins also saw some improvement, reinforcing the view that Tesla may well be entering recovery mode after a rocky start to the year. But for now, at least, it doesn't look like this was enough. The Report Was Better, But Not Good Enough With the stock's price-to-earnings (P/E) ratio looking quite frothy around the 180 mark, Tesla would have known in advance that expectations were sky-high. Anything short of a beat-and-raise quarter was going to be a letdown, and that's exactly how the post-release price action looks to be playing out. Shares were down more than 6% ahead of Thursday's open, confirming investor sentiment is turning cautious, at least in the short term. It's a reminder of just how high the bar has become for Tesla, and how little margin for error there is right now. Even with improving fundamentals, the recent rally looks to have gotten a bit ahead of itself. There's Still a Bull Case Here However, for longer-term investors on the sidelines, this pullback could be the opportunity we've been waiting for. In between the headline numbers were plenty of reasons to stay bullish. CEO Elon Musk reiterated that plans for a lower-cost vehicle remain on track for the second half of 2025, while forecasting that the company's robotaxi rollout will reach half the U.S. population by the end of the year. That's a big claim, and one that reinforces the innovation engine still driving the Tesla story and makes bulls so excited. It also pays to remember that the company rallied nearly 70% after last quarter's miss, which was far worse than this one. If anything, Q2's report, while not spectacular, showed progress. And that should be enough to support the next leg of the uptrend once the dust settles. Analysts Still Back the Long Game Backing up the theory that this could be a buy-the-dip opportunity, earlier this week, the team over at Wedbush reiterated their Outperform rating and $500 price target on Tesla shares. Not only is this pointing to a targeted upside of some 50%, it also echoes the similarly bullish calls from the likes of Cantor Fitzgerald and Mizuho earlier this month. While Tesla remains one of the most hotly debated stocks on the market, there's no denying that many on Wall Street, who are still backing its longer-term prospects, will be licking their chops today. Yes, there are headwinds. Regulatory scrutiny, rising costs, and weak free cash flow all remain overhangs. But the roadmap is still intact, and the market tends to look forward, especially when a company with Tesla's brand power is showing signs of stabilizing. A Pullback, Then a Reset Still, with shares looking likely to fall after last night's earnings, a short-term correction is likely. A move back towards the $290 level would be a healthy test of support and could give the bulls room to regroup. This is still a stock to watch closely, and a sell-off doesn't mean the rally is over; just that it might be on pause. If investor sentiment can reset around Tesla's improving deliveries, growing margins, and product innovation, the stock could soon be up for another strong run through the rest of Q3. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...